Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff
Nano-Ivermectin Impregnated Masks Versus Ordinary Surgical Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff
1 other identifier
interventional
150
1 country
1
Brief Summary
Antiviral efficacy of Ivermectin against Covid-19 in vitro was stated by many stusies all over the world with decreased effecacy in vivo so ,usage of masks impregnated into nano Ivermectin solution will theoretically increase the protective action of the ordinary masks
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable covid19
Started Jan 2021
Shorter than P25 for not_applicable covid19
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 20, 2021
CompletedStudy Start
First participant enrolled
January 23, 2021
CompletedFirst Posted
Study publicly available on registry
January 25, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 19, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
March 28, 2021
CompletedMarch 17, 2021
March 1, 2021
27 days
January 20, 2021
March 15, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of persons in each group who Complain of any suspected Symptoms
( Fever, Myalgia ,Cough, Sore Throat, Diarrhea, Shortness of Breath)
within 14 days after enrollement
Secondary Outcomes (1)
Number of persons in each group who are diagnosed as COVID-19 patients
within 21 days after enrollement
Study Arms (2)
Ivermectin mask group
ACTIVE COMPARATORContacts who will use ivermectin masks
ordinary mask group
NO INTERVENTIONContacts who will use regular masks
Interventions
Eligibility Criteria
You may qualify if:
- health care personells and family contact of confirmed COVID-19 cases.
You may not qualify if:
- refusal of participate to use the masks.
- pregnancy or lactation known hypersensitivity to ivermectin.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zaky Aref
Qina, 83511, Egypt
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- PREVENTION
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- ass.professor
Study Record Dates
First Submitted
January 20, 2021
First Posted
January 25, 2021
Study Start
January 23, 2021
Primary Completion
February 19, 2021
Study Completion
March 28, 2021
Last Updated
March 17, 2021
Record last verified: 2021-03
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR